Information Provided By: 
Fly News Breaks for April 7, 2015
CELG
Apr 7, 2015 | 07:24 EDT
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.
News For CELG From the Last 2 Days
There are no results for your query CELG
